Skip to main content
Fig. 1 | Journal of Experimental & Clinical Cancer Research

Fig. 1

From: p65BTK is a novel potential actionable target in KRAS-mutated/EGFR-wild type lung adenocarcinoma

Fig. 1

p65BTK is overexpressed in advanced lung adenocarcinomas with wild type EGFR from never-smoker patients. a IHC analysis of p65BTK in lung cancer tissue samples from a cohort of NSCLC patients using the BN30 antibody. Representative images of normal lung and lung cancer tissues are shown. SCC: squamous cell carcinoma; AdC/S: adenocarcinoma from smoker patient; AdC/NS: adenocarcinoma from non-smoker patient. Scale bar 100 μM. b Quantification of p65BTK expression in SCC and AdC patients. ***, p < 0.0001 by unpaired t test with Welch’s correction. c Quantification of p65BTK expression in smoker and non-smoker patients AdC and SCC patients. NS: non-smoker; S: smoker. Quantification of p65BTK expression. d Quantification of p65BTK expression in smoker and non-smoker AdC patients with either wild type (WT) or mutated (MT) EGFR. *, p = 0.04; ***, p < 0.0001 by non-parametric t test. e Quantification of p65BTK expression in primary NSCLC according to pN status. *, p = 0.04 by unpaired t test with Welch’s correction. f IHC analysis of p65BTK in metastatic lymph nodes of lung adenocarcinomas (AdC) or squamous cell carcinoma (SCC). Representative images show different expression levels of the kinase in the metastatic setting. Scale bars 500 μm (top panels) or 200 μm (lower panels)

Back to article page